Description
Lodonak bp
Lodonak bp 8/90 mg is a fixed-dose combination of naltrexone and bupropion. The verified medicine class is an anti-obesity preparation used for chronic weight management in adults when combined with diet and physical activity. The product name itself is not an internationally standard brand, so this summary is based on the consistently verified active ingredients and the same 8 mg/90 mg strength used by approved naltrexone/bupropion extended-release products.
Active Ingredient and Medicine Class
Naltrexone is an opioid receptor antagonist. Bupropion is a norepinephrine and dopamine reuptake inhibitor. Together, they form a centrally acting combination medicine for weight management. Regulatory sources classify this combination as a prescription medicine for obesity management.
Established Medical Uses
Verified regulatory information supports use of naltrexone/bupropion as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity, or for adults with overweight who also have weight-related comorbidities such as hypertension, dyslipidaemia, or type 2 diabetes. The medicine is intended for weight management rather than treatment of depression or opioid dependence.
How It Works
The exact mechanism is not fully understood. EMA information states that the two active substances act on brain pathways involved in food intake and energy balance, and they also reduce the reward-related pleasure associated with eating. In practical terms, this helps explain its role in appetite and craving control.
Important Safety Information
Important contraindications and precautions include seizure disorder or a history of seizures, eating disorders such as bulimia or anorexia nervosa, abrupt withdrawal from alcohol, benzodiazepines, barbiturates or antiepileptic drugs, and current opioid use or acute opioid withdrawal. It should not be used with other bupropion-containing products, and coadministration with opioid-containing medicines may be problematic because naltrexone blocks opioid effects. The FDA label also warns about suicidal thoughts and behaviour, especially in younger patients, and notes that cardiovascular morbidity and mortality benefit has not been established.
Possible Side Effects
Common adverse effects reported in clinical studies and product information include nausea, constipation, headache and vomiting. Other clinically important reactions may include increases in blood pressure or heart rate, insomnia, dizziness, and neuropsychiatric symptoms. Serious but less common risks include seizures and suicidal thoughts or behaviour.
Scientific Evidence
Peer-reviewed reviews of randomized trials found that naltrexone/bupropion produced greater weight loss than placebo over 56-week studies and improved several cardiometabolic markers in some populations. The benefit was generally described as modest but clinically meaningful for selected patients, with nausea as the most frequent adverse event.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA) — Mysimba: EPAR – Product Information
- U.S. Food and Drug Administration (FDA) — CONTRAVE Prescribing Information
- Greig SL, Keating GM, et al. — “Naltrexone ER/Bupropion ER: A Review in Obesity Management.” Drugs. 2015. PubMed